Nkar­ta trims head­count as it sets sights on au­toim­mune cell ther­a­py

Nkar­ta will let go about 10% of its work­force as it fo­cus­es on ap­ply­ing off-the-shelf cell ther­a­py to an au­toim­mune dis­ease, it dis­closed in an SEC fil­ing Tues­day morn­ing.

The re­duc­tion of 18 po­si­tions will oc­cur by the end of this year and is ex­pect­ed to ex­tend the South San Fran­cis­co biotech’s run­way by one year in­to 2026, Nkar­ta said in a press re­lease, not­ing it had about $278 mil­lion in cash at the end of Sep­tem­ber. The com­pa­ny said it will al­so con­sol­i­date op­er­a­tions “to a sin­gle lo­ca­tion” and lim­it fu­ture hir­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER